Company spokeswoman Maryann Caprino described FitzGerald's article as "an interesting hypothesis" but said that "in terms of the real world, we totally disagree."
 The FDA said last week after Vioxx was withdrawn that the problems were unique to that drug . But FitzGerald suggested that by selectively blocking one of the two substances called prostaglandins that lead to inflammation, these Cox-2 inhibitors were sparing the stomach at the expense of the heart.